lution containing either various doses (0.01, 0.1 and 1 g) of recombinant hIL-17 or 2.5 ng of recombinant rIL-1 ␤ (R&D Systems Europe Ltd, Abingdon, UK) or corresponding vehicle was injected and flushed with 3 ml of air to deliver the solution to the lung. The dose of rIL-1 ␤ was chosen based upon separate dose-response experiments in our SD rat model (Hoshino and coworkers, unpublished data). Separate experiments showed that the drug solution was distributed evenly from the trachea to small bronchi, using this intratracheal instillation procedure. The negative control animals received the vehicle of the cytokines. This vehicle consisted of sterile PBS with 0.21% bovine serum albumin (BSA)(Grade V; Sigma Chemical Co., St. Louis, MO) and 0.1 ng lipopolysaccharide (LPS) ( Escherechia coli serotype O55: B5; Sigma Chemical) because each cytokine per se contains a small amount of LPS ( Ͻ 0.1 ng/ g of cytokine according to the manufacturer). After intratracheal instillation, the rats were allowed to regain consciousness.
Bronchoalveolar Lavage
Bronchoalveolar lavage fluid (BAL) was obtained 6 h after the intratracheal instillation of cytokines or corresponding vehicle. After receiving 300 mg/kg pentobarbital sodium (Apoteksbolaget, Umeå, Sweden) intraperitoneally, which is a lethal dose, a tracheal cannula (10 mm long and 2.7 mm internal diameter) was inserted into the upper cervical trachea through a tracheotomy. BAL was collected in a plastic tube on ice after gentle, manual instillation and withdrawal of 4 ml of sterile PBS five times using a syringe through the intratracheal cannula (20 ml total volume). There was no significant difference in BAL recovery volume between groups. The fluids were centrifuged (200 ϫ g for 10 min at 4 Њ C), and the cell pellet was resuspended in washing buffer containing sterile PBS with 0.35% BSA and 0.1% glucose. Total BAL cell counts were determined in a hemocytometer using Türk solution. For differential BAL cell counts, cytospin preparations were stained with May-Giemsa. Differential cell counts were conducted according to standard morphology criteria using oil immersion microscopy (magnification: ϫ 1,000). Cell counts were carried out on 300 cells, and the absolute number of each cell type was calculated. The cell-free BAL was collected and stored at Ϫ 80 Њ C.
Peptidase-inhibition versus Neutrophil Recruitment
Induced by hIL-17 or rIL-1 ␤ The combination of the selective neutral endopeptidase (NEP) inhibitor phosphoramidon (0.4 mM, 60 breaths; Sigma Chemical Co.) and the selective angiotensin-converting enzyme (ACE) inhibitor captopril (4.6 mM, 60 breaths; Sigma Chemical Co.) or vehicle (0.9% saline, 60 breaths) was inhaled as an aerosol 30 min prior to intratracheal instillation of each cytokine or the corresponding vehicle (12) .
In separate experiments, phosphoramidon or captopril or vehicle was inhaled, as described above, prior to intratracheal instillation of hIL-17 or the corresponding vehicle. Aerosols were generated with an ultrasonic nebulizer (Model 2511 PulmoSonic; DeVilbiss Co, Somerset, PA), and were administered intratracheally through a cannula using a ventilator system (Model 50-1718; Harvard Apparatus Ltd., South Natik, MA)
Neurokinin Receptor Antagonism versus Neutrophil Recruitment Induced by hIL-17
The selective NK-1 receptor antagonist, SR 140333 (15) . Control animals received the corresponding vehicle (same volume of ethanol in saline). For both SR 140333 and SR 48968, respectively, the described experiments were repeated in separate rats receiving pretreatment with inhalation of phosphoramidon 30 min prior to the intraperitoneal instillation of hIL-17.
rIL-1 ␤ level in BAL
Levels of rIL-1 ␤ (pg/ml) in BAL from rats treated with hIL-17 (1 g) or the corresponding vehicle were assessed using ELISA (R&D Systems Europe Ltd) for rIL-1 ␤ .
Data Analysis
Experiments were conducted with a randomized, matched design; animals from the same batch were utilized for intervention and control experiments in parallel during the same experimental day. Data are expressed as mean Ϯ SEM. Statistical differences between groups were evaluated using Student's t test (unpaired one-or two-way) in the case of two groups. Analysis of variance (Kruskal-Wallis followed by Mann-Whitney U-test) was used in the case of more than two treatment groups. The relationship between the dose of IL-17 and the neutrophil count was analyzed using Spearman's rank correlation. A standard statistical package (StatView, Abacus Concept, Berkeley, CA) and a Macintosh computer (Apple Computer Inc, Cupertino, CA) were utilized. A p value less than 0.05 was regarded as significant. 
RESULTS

Intratracheal Instillation of hIL-17 and rIL-1 ␤
Intratracheal instillation of hIL-17 induced a selective and significant increase of the neutrophil count in BAL ( Figure 1A ) and this increase was dose-dependent ( Figure 2 ). In contrast, intratracheally administered hIL-17 induced no significant increase in macrophage, eosinophil, or lymphocyte counts in BAL ( Figure 1A ). Similar to that of hIL-17, intratracheally instilled rIL-1 ␤ induced a selective and significant increase of the neutrophil count in BAL ( Figure 1B) . The increase in neutrophil count induced by 1 g of hIL-17 (6.3 nmol) displayed a similar order of magnitude as that induced by 2.5 ng of rIL-1 ␤ (14.7 pmol).
Peptidase-inhibition versus Neutrophil Recruitment
Induced by hIL-17 or rIL-1 ␤ Inhalation of phosphoramidon plus captopril significantly enhanced the neutrophil count in BAL, for rats receiving hIL-17 or rIL-1 ␤ instilled intratracheally (Figure 3 ). In contrast, the eosinophil count was not enhanced by inhalation of the peptidase inhibitors prior to intratracheally instilled hIL-17. The eosinophil count in BAL was 0.003 Ϯ 0.002 ϫ 10 6 /ml, using inhalation of vehicle, and 0.001 Ϯ 0.001 ϫ 10 6 /ml, using inhalation of phosphoramidon plus captopril prior to hIL-17 instillation. Correspondingly, the eosinophil count was 0.008 Ϯ 0.008 ϫ 10 6 /ml, using inhlation of vehicle, and 0.004 Ϯ 0.002 ϫ 10 6 /ml, using inhalation of phosphoramidon plus captopril prior to intratracheal instillation of rIL-1 ␤ . Inhalation of phosphoramidon alone significantly enhanced the neutrophil count in BAL (Figure 4 ), whereas inhalation of captopril did not, in rats receiving intratracheal instillation of hIL-17.
Selective NK-receptor Antagonism versus Neutrophil Recruitment Induced by hIL-17
Pretreatment intraperitoneally with the selective NK-1 receptor antagonist SR 140333 attenuated the neutrophil count in BAL, in rats given hIL-17 intratracheally ( Figure 5A ). In contrast, intraperitoneal pretreatment with the selective NK-2 receptor antagonist SR 48968 did not attenuate the neutrophil count in BAL in rats given hIL-17 intratracheally ( Figure 5B ). The specific effect of SR 140333, but not that of SR 48968, was even more pronounced after pretreatment with phosphoramidon ( Figure 6A ).
rIL-1 ␤ Level in BAL
Measuring rIL-1 ␤ in BAL, we found no significant difference (p Ͼ 0.05, n ϭ 9) for hIL-17-versus vehicle-treated rats (hIL-17: 65.8 Ϯ 7.51 pg/ml, versus vehicle: 63.6 Ϯ 8.02 pg/ml). Figure 1) is also shown. The neutrophil count in BAL was determined 6 h after instillation of either cytokine or the corresponding vehicle (see Figure 1) . Values shown are mean Ϯ SEM (n ϭ 6 to 7). *p Ͻ 0.05, NS ϭ not significant versus rats treated with the vehicle of phosphoramidon and captopril, according to Student's t test (unpaired, two-way). 
DISCUSSION
This study shows that intratracheal instillation of hIL-17 causes dose-dependent neutrophil recruitment into airways and this recruitment is enhanced by selective inhibition of NEP and it is attenuated by NK-1-receptor antagonism in SD rats in vivo. The study also shows that the selective neutrophilrecruiting effect of hIL-17 is mimicked by rIL-1␤, although hIL-17 per se does not increase rIL-1␤.
Mucosal biopsies from patients with newly diagnosed asthma display an increased number of neutrophils and lymphocytes (16) . A significant number of neutrophils has also been observed in the sputum of asthmatic patients during obstructive exacerbations, with or without infections, indicating a role for neutrophils in acute airway inflammation (17, 18) . There is also corresponding evidence of the role of neutrophils in chronic airway inflammation; samples from patients with chronic bronchitis who smoke display an increased number of neutrophils and T-lymphocytes in the vicinity of mucosal glands when compared with asymptomatic smokers (19) . Hypothetically, activated neutrophils may induce hypersecretion in bronchial glands via the release of the potent secretagoge neutrophil elastase (20) , but little is known about the mechanistic relationship between the T-lymphocytes and neutrophils.
We now demonstrate that the neutrophil recruitment induced by intratracheal instillation of the T-lymphocyte cytokine hIL-17 is dose-dependent and as selective as it is for the species homologue macrophage cytokine rIL-1␤ in rat airways in vivo. It has previously been demonstrated that hIL-1␤ recruits neutrophil in rat airways and mouse air pouch (21, 22) . Our observation that IL-1␤ was not increased by IL-17 instilled intratracheally argues against IL-17 recruiting neutrophils via IL-1␤. Because CD4ϩ and CD8ϩ cells constitute the only known sources of IL-17 (5-7, 23), our findings indicate that IL-17 can link the activation of T-lymphocytes to neutrophil recruitment.
On a molar basis, the potency of hIL-17 is weaker than that of rIL-1␤ in inducing neutrophil recruitment in rat airways in vivo. Hypothetically, this difference in potency could be attributed to species heterogenity. However, separate experiments (Hoshino and colleagues, unpublished data) have confirmed that mouse (m) IL-17 and hIL-17 are equipotent in the rat and that mIL-17 and rIL-17 display a 90% amino acid homology and a highly conserved glycosylation site (24) . This does not point out species heterogeneity as an explanation of why hIL-17 is less potent than rIL-1␤ in the airways. It is possible that IL-17 is less potent than IL-1␤ because of its mechanism of action, which may involve release of other neutrophil-recruiting mediators, but this mechanism does not involve secondary release of IL-1␤.
We also demonstrated that the neutrophil recruitment induced by hIL-17 is significantly depressed by endogenous NEP (EC 3.4.24.11, enkephalinase). We did this by showing that pretreatment with combined inhibition of NEP of ACE (EC 3.4.15.1, kininase I) as well as inhibition of NEP alone enhances neutrophil recruitment. In contrast, we found that inhibition of ACE alone had no such effect. Both NEP and ACE degrade endogenous peptides and may be important in regulating various inflammatory responses in the airways (12, (24) (25) (26) . Our study therefore indicates that endogenous peptides are involved in modulating the neutrophil response to hIL-17 as well. This modulation may be universal for neutrophil-recruiting cytokines because we found that combined inhibition of NEP of ACE enhanced neutrophil recruitment induced by hIL-17 as well as that induced by rIL-1␤. In support of our findings, previous studies have indicated that neutrophil recruitment is depressed by NEP, using stimuli other than cytokines (11, 27) . The fact that NEP is located mainly in the lining airway epithelium, whereas ACE is located mainly in vascular endothelium within the airway wall (24, 25, 28) , also makes NEP the more likely candidate of the two for modulation of neutrophil recruitment into the airways. Thus, if secreted in the airways by T-lymphocytes, IL-17 probably releases peptides primarily from nerve endings close to the lining epithelium, where these peptides can subsequently be degraded by NEP.
It has previously been reported that NEP, in addition to ACE, may regulate blood pressure via degradation of SP and bradykinin (29) . To minimize the risk of such indirect, unspecific effects on neutrophil recruitment, we administered the peptidase inhibitors locally, by inhalation. The results of our study also provide several arguments against such unspecific effects. First, the combined pretreatment with inhibitors of NEP and ACE did not significantly alter the neutrophil count under baseline conditions (i.e., rats receiving the vehicle of IL-17 alone; see METHODS). Second, the very low eosinophil count in BAL from rats treated with hIL-17 or rIL-1␤ was not increased by inhibition of NEP plus ACE. This contrasts to the neutrophil count and it is unlikely that a significant change in blood pressure would affect the neutrophil count and leave other types of cell counts unaltered. Third, in the case of hIL-17, inhibition of NEP, but not inhibition of ACE, increased neutrophil recruitment similarly to inhibition of NEP plus ACE. If an unspecific mechanism would be the case, then inhibition of ACE, located in vascular endothelium, should cause more effect than inhibition of NEP. Fourth, a bradykinin receptor antagonist inhibited neutrophil recruitment induced by IL-1␤ in a previous study, and tachykinins are known to mediate bradykinin responses (30) .
We also found that a selective NK-1 receptor antagonist attenuates the neutrophil recruitment by hIL-17, whereas a selective NK-2 antagonist does not. This specific effect of NK-1 receptor antagonism was even more evident in rats pretreated with the NEP inhibitor phosphoramidon, suggesting that the neutrophil response to hIL-17 is modulated by endogenous tachykinins acting mainly via NK-1 receptors. In this context, the dominating tachykinin is likely to be substance P (SP), because NK-1, NK-2, and NK-3 receptors are primarily targeted by SP, NKA, and NKB, respectively (31, 32) . We find it unlikely that the lack of effect of the NK-2 antagonist was due to a too low dose because we utilized a dose that has clear antiinflammatory effects in vivo (14, 32) . The effect of the NK-1 receptor antagonist also argues against the hypothetical possibility that NEP degrades IL-17 protein per se. Peptidase degradation of rIL-1␤ appears unlikely as well, because NEP does not hydrolyze human IL-1␤ (33) .
The inhibitory effect on neutrophil recruitment caused by the NK-1 receptor antagonist was partial (25 to 40%). It is therefore possible that other peptide mediators, in addition to endogenous tachykinins, are involved in modulating the neutrophil response to hIL-17 in airways in vivo. Bradykinin, for example, may play a role in modulating the neutrophil response to hIL-17, because tachykinins are associated with bradykinin-induced airway responses (34, 35) .
Although no previous study has focused on cytokine-induced neutrophil recruitment into the lower airways, several previous studies support the idea that endogenous tachykinins (possibly SP) modulate neutrophil recruitment. In rat airways, SP potently increases adhesion and transvascular migration of neutrophils (24) . SP also induces neutrophil chemotaxis both in vivo (36) and in vitro for human (37) and rat (38) cells, respectively. In addition, a NK-1 receptor antagonist reduces the number of neutrophils in airways after allergen challenge in sensitized mice (39) . In rats, a NK-1 receptor antagonist even blocks neutrophil adhesion (9) . Taken together, all these findings are compatible with tachykinins (possibly SP) modulating neutrophil recruitment into the airways by acting on NK-1 receptors.
In conclusion, this study on rats has shown that the T-lymphocyte cytokine IL-17 selectively and dose-dependently can recruit neutrophils into airways in vivo and this effect is modulated by endogenous tachykinins acting mainly on NK-1 receptors. If a similar mechanism exists in human airways, NK-1 receptor antagonists may be effective in treating airway inflammation involving neutrophils.
